Phillip Md Et Al Frost Purchases 675,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

Key Points

• OPKO Health CEO Phillip Md Et Al Frost acquired 675,000 shares at $1.32 each, amounting to a total of $891,000, increasing his ownership by 0.32% to approximately $283 million.
• The company's latest earnings report revealed a loss of ($0.19) EPS, falling short of estimates, with revenue dropping 13.9% year-over-year to $156.80 million.
• As of now, OPKO Health holds a market capitalization of about $992.23 million, with a consensus rating of "Moderate Buy" and an average price target of $2.75 from analysts.

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 675,000 shares of OPKO Health stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $1.32 per share, with a total value of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

OPKO Health Trading Up 1.9%

OPK stock traded up $0.03 during midday trading on Wednesday, reaching $1.35. 300,670 shares of the company's stock traded hands, compared to its average volume of 3,874,872. The business has a 50-day moving average price of $1.33 and a two-hundred day moving average price of $1.47. OPKO Health, Inc. has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company has a market capitalization of $1.07 billion, a P/E ratio of -5.38 and a beta of 1.19.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The company had revenue of $156.80 million during the quarter, compared to the consensus estimate of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%. The firm's quarterly revenue was down 13.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) EPS. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Thursday, May 1st. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating for the company. Wall Street Zen downgraded shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. Finally, LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, OPKO Health presently has a consensus rating of "Moderate Buy" and an average target price of $2.75.

Institutional Trading of OPKO Health

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in OPKO Health by 68.7% during the fourth quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock valued at $1,347,000 after purchasing an additional 373,032 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of OPKO Health during the first quarter worth about $585,000. Bank of America Corp DE grew its position in shares of OPKO Health by 94.7% during the fourth quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock worth $855,000 after acquiring an additional 282,844 shares during the last quarter. Two Sigma Investments LP grew its position in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after acquiring an additional 949,671 shares during the last quarter. Finally, GSA Capital Partners LLP grew its position in shares of OPKO Health by 24.2% during the first quarter. GSA Capital Partners LLP now owns 1,343,701 shares of the biotechnology company's stock worth $2,231,000 after acquiring an additional 261,495 shares during the last quarter. Institutional investors own 64.63% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.